Loading organizations...

Atox Bio is a technology company.
Atox Bio is a late-stage critical care immunotherapy company focused on acute, life-threatening conditions. Its lead product, Reltecimod (AB 103), is an immunomodulator peptide. This treatment modulates the body's inflammatory response, addressing organ dysfunction or failure in critically ill patients with severe infections, including necrotizing soft tissue infections (NSTI).
Professor Raymond Kaempfer and Dr. Gila Arad established Atox Bio in 2003. Both founders, from the Hebrew University of Jerusalem's faculty of medicine, leveraged academic research into immunological responses. This foundational scientific work, developed with Yissum, the university’s technology transfer company, provided the basis for their therapeutic approach.
The company's pipeline targets critically ill patients with severe infections, like necrotizing soft tissue infections, experiencing organ dysfunction or failure. Atox Bio aims to improve clinical outcomes by addressing unmet medical needs in critical care, advancing immunomodulatory treatments for more effective options in life-threatening conditions.
Atox Bio has raised $56.3M across 3 funding rounds.
Atox Bio has raised $56.3M in total across 3 funding rounds.
Atox Bio is a late-stage biotechnology company developing Reltecimod (also known as AB103), an immunomodulator designed to treat acute, life-threatening conditions like necrotizing soft tissue infections (NSTI, or "flesh-eating disease") and sepsis-associated acute kidney injury (SA-AKI).[1][2][3] It serves critically ill patients in intensive care settings, addressing unmet needs in severe inflammation where no effective therapies currently exist, such as enhancing organ failure resolution in NSTI and SA-AKI, which affects ~50% of sepsis patients and carries high mortality.[1][2] The company has shown growth momentum through completed Phase 3 enrollment for NSTI (ACCUTE trial), ongoing Phase 3 for SA-AKI, Phase 2 success in NSTI demonstrating endpoint improvements, and FDA/EMA Orphan Drug plus FDA Fast Track designations.[1][2][3]
Founded in 2003, Atox Bio emerged as a biotech focused on novel immunomodulators for critically ill patients, with current CEO Dan Teleman leading operations.[2] The company advanced from early research to late-stage development, with its lead candidate Reltecimod progressing through Phase 2 (showing meaningful improvements in NSTI patients) to pivotal Phase 3 trials for NSTI and SA-AKI, marking key traction in addressing high-mortality conditions without prior therapies.[1][2]
Atox Bio rides the trend of precision immunomodulation in critical care biotech, where rising sepsis and antimicrobial-resistant infections amplify demand for therapies beyond antibiotics.[1][2] Timing aligns with post-pandemic focus on acute inflammatory diseases, as NSTI and SA-AKI contribute to ICU burdens without approved treatments, bolstered by regulatory fast-tracks amid orphan disease incentives.[1][3] Market forces like aging populations and infection surges favor its pipeline, while success could influence ecosystem by validating peptide-based immunomodulators, encouraging investment in rare-disease critical care and reducing sepsis-related mortality ecosystem-wide.[1][2]
Atox Bio's Phase 3 readouts for Reltecimod in NSTI and SA-AKI position it for potential near-term approvals, unlocking first-in-class status in underserved critical care markets.[1][2] Evolving trends like AI-driven trial design and combo therapies with antimicrobials could accelerate adoption, while expanded indications in severe infections might broaden impact. Its influence may grow by pioneering immunotherapy resolution in inflammation, tying back to its core mission of transforming outcomes for the critically ill.
Atox Bio has raised $56.3M in total across 3 funding rounds.
Atox Bio's investors include Jonathan Tobin, Brandon Capital Partners, Terry Gould, Asahi Kasei, Becker Ventures, Integra Holdings, Lundbeckfond Ventures, OrbiMed, SR One, Matthew Foy, Casper Breum, Erez Chimovits.
Atox Bio has raised $56.3M across 3 funding rounds. Most recently, it raised $30.0M Series F in December 2017.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2017 | $30.0M Series F | Jonathan Tobin | Brandon Capital Partners, Terry Gould, Asahi Kasei, Becker Ventures, Integra Holdings, Lundbeckfond Ventures, OrbiMed, SR One |
| Jul 24, 2014 | $23.0M Series E | Matthew Foy | Casper Breum, Erez Chimovits |
| Dec 19, 2011 | $3.3M Other Equity | Dean Slagel |